1. Introduction {#sec1}
===============

Lung cancer accounts for a large proportion of cancer patients worldwide and is the leading cause of cancer-related deaths \[[@B1]\]. There were 9.6 million cancer-related deaths in 2018, 18.4% of which were caused by lung cancer \[[@B2]\]. In China, about 28% and 23% of cancer-related death in 2012 occurred as a result of lung cancer in men and women, respectively. Non-small-cell lung cancer (NSCLC), including lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC), accounts for approximately 85% of all lung cancers \[[@B3]\]. With a better understanding of tumor biology, there has been a breakthrough in the treatment of lung cancer. However, radiotherapy, either alone or with chemoradiotherapy, is still the primary treatment or palliative care for many patients, especially for locally advanced NSCLC patients who cannot be surgically resected. There is often a significant difference in treatment effects and toxic reactions in NSCLC patients undergoing standard radiotherapy \[[@B4], [@B5]\]. Genetic variations between individuals or tumors are the main reasons for the differences in sensitivity to radiotherapy \[[@B6]\].

Ionizing radiation leads to cell death mainly by creating double-strand breaks (DSB) \[[@B7]\] or through damage to cell membranes \[[@B8]\]. Studies have shown that DNA repair genes, such as *ERCC1* \[[@B9]\], *XRCC1* \[[@B10]\], and *XPA* \[[@B11]\], play a key role in the different repair processes that are invoked in cells following DNA damage. There are several DNA repair pathways in the human body, of which the nucleotide excision repair (NER), mismatch repair (MMR), and homologous recombination (HR) systems repair the damaged DNA after the formation of cross-link chains, whereas the base excision repair (BER) pathway repairs it before the formation of cross-link chains. *XRCC1* and *XRCC2* are involved in the BER and HR pathways, respectively, and have been associated with the occurrence of cancer \[[@B12], [@B13]\]. *MutS homolog 2 (MSH2)*, a key component of the MMR pathway, plays an important role in the development of neoplastic diseases \[[@B14]\]. The *Xeroderma pigmentosum group D* (*XPD*) gene, another important DNA repair gene, has been reported to contribute to the risk of human cancer \[[@B15]\].

Although the relationship between polymorphisms in DNA repair genes and the development of cancer has been well explored in previous studies, few reports have investigated the interrelationship between gene polymorphisms and radiosensitivity or radiotherapy toxicity in patients with NSCLC. To explore the possible association between DNA repair gene variations and radiotherapy sensitivity and associated toxicity, we evaluated eleven single nucleotide polymorphisms (SNPs) in four DNA repair genes (*XRCC1*, *XRCC2*, *XPD*, and *MSH2*).

2. Materials and Methods {#sec2}
========================

2.1. Study Population {#sec2.1}
---------------------

In this study, a total of 486 histologically confirmed NSCLC patients were recruited from the Shengjing Hospital of China Medical University from July 2015 to September 2019. The detailed characteristics of these patients are described in [Table 1](#tab1){ref-type="table"}. The inclusion criteria were as follows: (1) patients who were diagnosed as having primary NSCLC and not eligible for surgery; (2) patients who underwent a lung biopsy and had a confirmed histopathological diagnosis of NSCLC; (3) patients who received a standard dose of radiotherapy; (4) patients who had no recurrent disease; (5) patients who had no other malignant tumors or history of radiotherapy. All participants or family members signed an informed consent form before blood collection and analysis. This study was approved by the ethics committee of the Shengjing Hospital of China Medical University.

2.2. Radiotherapy Treatment and Evaluation {#sec2.2}
------------------------------------------

All patients were treated with three-dimensional conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT), with a total radiation dose of 50--70 Gy. Followups were conducted on all patients three months after radiotherapy, and their response to treatment was assessed using computed omography (CT) according to the Response Evaluation Criteria in Solid Tumors (RECIST) guidelines. There were four categories of response defined: complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) \[[@B16]\]. In the present study, CR and PR were grouped as "responders," whereas SD and PD were grouped as "nonresponders." Radiation-induced toxic reactions were graded according to the Radiation Therapy Oncology Group or European Organization for Research and Efficacy of Cancer (RTOG/EORTC) guidelines. Patients with grade 0 and grade 1 reactions were considered to have "low-toxic reactions" and those with grades 2--5 reactions, "high-toxic reactions."

2.3. Selection of SNPs and Genotyping {#sec2.3}
-------------------------------------

Four DNA repair genes, *XRCC1*, *XRCC2*, *MSH2,* and *XPD*, which had previously been shown to be positively associated with the development of cancer, were selected for analysis. SNP genotypes were downloaded from the 1000 Genomes project (<https://www.internationalgenome.org/>) and analyzed using Haploview 4.2 software (<https://www.broadinstitute.org/haploview/haploview>). Candidate SNPs which met the following criteria were included: (1) SNPs that had a minor allele frequency (MAF) \> 0.1 in Han Chinese in Beijing (CHB); (2) SNPs with a potential function, such as missense variations causing amino acid changes or were present in the 5′ or 3′ untranslated regions (UTRs) that could affect transcription factor binding site (TFBS) activity; (3) SNPs that have been reported in previous association studies. As a result of using these selection criteria, a total of 11 potentially functional SNPs in DNA repair genes were selected. These included 4 *XRCC1* SNPs (rs25487 (exon 10), rs25489 (exon 9), rs1799782 (exon (6) and rs3213245 (5′ UTR)), 3 *XRCC2* SNPs (rs3218556 (3′ UTR), rs3218544 (3′ UTR), rs3218385 (5′ UTR)), 2 *MSH2* SNPs (rs2303424 (exon 16) and rs2303425 (5′ UTR)), and 2 *XPD* SNPs (rs13181 (exon 10) and rs238419 (3′ UTR)).

Genomic DNA from all patients was extracted using a TIANamp Genomic DNA Kit (Tiangen Biotech, Beijing, China). Genotyping was performed using the TaqMan methodology and an Applied Biosystems 7500 FAST Real-Time PCR System (Applied Biosystems, Foster City, CA, USA) according to the manufacturer\'s instructions. The predesigned SNP-genotyping assay mixture, containing the PCR primers and probes, were supplied by Applied Biosystems. The PCR amplification mix was prepared as follows: 25 *μ*L of master mix (Applied Biosystems), 10 *μ*L of DNA, and 15 *μ*L of ddH~2~O. Amplification was performed under the following conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles of 95°C for 15 sec, 60°C for 1 min. Three negative controls (no DNA) and three positive controls in each 96-well plate were used to ensure the accuracy of the PCR amplification. In addition, 10% of randomly repeated samples were used for quality control.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Statistical analyses were performed using SPSS 22.0 software (SPSS, Chicago, IL, USA). The Hardy-Weinberg equilibrium was used to assess that all SNPs met the group representation. A multiple factor logistic regression was applied to assess the association between SNPs and efficacy of radiotherapy as well as radiation-induced toxicity reaction after adjusting for age, gender, smoking history, cancer histology, family history, and chemotherapy. A *p* \< 0.05 was considered statistically significant.

3. Results {#sec3}
==========

3.1. Characteristics of Patients and Clinical Outcomes {#sec3.1}
------------------------------------------------------

The clinical characteristics and demographics of the 486 NSCLC patients are described in [Table 1](#tab1){ref-type="table"}. The proportion of male patients (67.5%) was greater than double the proportion of female patients (32.5%). The median age of all patients was 62 (ranging from 33 to 84). About half of the patients had a history of smoking. There were 307 (63.2%) cases of squamous cell carcinoma and 179 (36.8%) cases of adenocarcinoma. Seventy-six patients (15.7%) had a family history of cancer and 383 (78.8%) had been treated with chemotherapy. The response rate to radiotherapy was 48.1%.

3.2. Associations between Candidate SNPs and Efficacy of Radiotherapy {#sec3.2}
---------------------------------------------------------------------

The associations between candidate SNPs and the response to radiotherapy in NSCLS patients are shown in [Table 2](#tab2){ref-type="table"}. All the candidate SNPs reached equilibrium according to the Hardy-Weinberg equilibrium test (*p* \> 0.05, data not shown). The SNPs rs25487 (*XRCC1*), rs3218556 (*XRCC2*), and rs13181 (*XPD*) all showed a significant association with the efficacy of radiotherapy. The allele frequency of rs25487 CC genotype (OR = 0.457, 95% CI = 0.259--0.804,*p*=0.006) and the rs3218556 AG or AA genotypes (AG genotype: OR = 0.664, 95% CI = 0.442--0.999,*p*=0.049; AA genotype: OR = 0.380, 95% CI = 0.181--0.795, *p*=0.008) were significantly higher in the response group than in the nonresponse group. For rs25487, although the response rate between the CT and CC genotypes was not statistically significant (*p*=0.078), a higher response rate was also observed when comparing the CT + CC genotype with the CC genotype, using a dominant model. For rs13181, a better radiotherapy efficacy was associated with the heterozygotic genotype GT (OR = 1.663, 95% CI = 1.057--2.614, *p*=0.027). There were no significant associations between the other SNPs and the efficacy of radiotherapy.

3.3. Associations between Candidate SNPs and Radiation-Induced Toxic Reactions {#sec3.3}
------------------------------------------------------------------------------

The associations between candidate SNPs and radiation-induced toxic reactions are shown in [Table 3](#tab3){ref-type="table"}. A statistically significant association between radiation-induced toxic reactions and rs25487 (*XRCC1*), rs3218556 (*XRCC2*), and rs13181 (*XPD*) was observed. For rs25487, the genotypes CT, TT, and CT + TT were associated with a severe toxic reaction compared to the CC genotype (all, *p* \< 0.05). For rs3218556, the ORs for cases with the AG, AA, and AG + AA genotypes compared with homozygous CC genotype were 0.605 (95% CI = 0.396--0.924, *p*=0.019), 0.279 (95% CI = 0.116--0.675, *p*=0.003), and 0.540 (95% CI = 0.362--0.805, *p*=0.002), respectively. The rs13181GT genotype was associated with lower toxic reactions compared with the TT genotype (OR = 1.680, 95% CI = 1.035--2.728, *p*=0.035).

4. Discussion {#sec4}
=============

NSCLC is the leading cause of cancer-related death. Radiotherapy is an important treatment for NSCLC patients, especially for advanced NSCLC patients. However, there are significant differences in the efficacy of radiotherapy as well as in the incidence rate for radiation-induced toxic reactions. Identification of the key determinants that affect efficacy and toxicity is of paramount importance for the efficacy of radiotherapy in patients with NSCLC. Although numerous studies have reported that genetic polymorphisms in DNA repair genes are related to the development of cancer, their association with the outcomes of radiotherapy remains unknown. In the present study, we demonstrated that rs25487 (*XRCC1*), rs3218556 (*XRCC2*), and rs13181 (*XPD*) were associated with the efficacy and toxicity of radiotherapy in patients with NSCLC.

The potential functional variations of the four DNA repair genes were listed in Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}. The variations of rs25487 (c.1196A \> G, p. Gln399Arg), rs25489 (c.839G \> A, p. Arg280His), rs1799782 (c.580C \> T, p. Arg194Trp) of *XRCC1* gene, rs2303424 (c.2744A \> G, p. Gln915Arg) of *MSH2* gene, and rs13181 (c.2251A \> C, p. Lys751Gln) of *XPD* gene cause amino acid changes and then affect the biological function of the protein. Also, other variations located in the 5′ or 3′ UTRs may affect the transcription factor binding site (TFBS) activity and then influence the DNA repair gene expression. All the variants may impact the clinical outcome of radiotherapy through these two ways.

Many genetic variants that are involved in DNA damage repair and the regulation of oxidative stress are associated with radiotherapy outcomes \[[@B17]\]. *XRCC1*, an important component of BER, has been reported to be associated with an increased risk of NSCLC in nonsmoking female patients with a history of exposure to cooking oil mist \[[@B10]\]. Genetic polymorphisms in *XRCC1*-194 and *XRCC1*-399 are also related to the risk of NSCLC \[[@B18]\]. Wang et al. \[[@B19]\] have reported that the presence of *XRCC1* rs25489 had a significant impact on primary tumor efficacy at the end of radiotherapy and may act as a biomarker for the curative effect of radiotherapy. Zhai et al. \[[@B20]\] found that patients with nasopharyngeal carcinoma (NPC) carrying the *XRCC1* codon 399 Gln/Gln genotype had a higher rate of tumor regression after radiotherapy. Another study showed that, in 114 patients with NPC, the *XRCC1* rs25487 GA genotype was related with grade 3 dermatitis and grade 3 mucositis. In this study, a significant association was also observed between the rs25489 CC genotype and a higher response rate to radiotherapy as well as lower toxic reaction. Although three other SNPs (rs25489, rs1799782, and rs3213245) in *XRCC1* were also genotyped, no significant associations were observed. Due to the fact that *XRCC1* rs25487 is clearly important in radiation sensitivity and the resultant toxic reactions, it could be considered as a biomarker that can be used to predict the clinical outcomes of radiotherapy.

Three SNPs (rs3218556, rs3218544, and rs3218385) in *XRCC2*, which is involved in the HR pathway, were also evaluated for a possible association with the efficacy and toxicity of radiotherapy in patients with NSCLC. Of these, only rs3218385 showed a significant association with both the efficacy and toxicity of radiotherapy. Popanda et al. \[[@B7]\] suggested that there was no relationship between the risk of acute skin toxicity and *XRCC2* variations in patients with breast cancer receiving radiotherapy, which is inconsistent with our findings. Nevertheless, Yin et al. \[[@B21]\] genotyped six potentially functional SNPs in 228 patients with NSCLC who had been treated with definitive radiotherapy and found that *XRCC2* R188H SNPs was independent prognostic factor for overall survival. Qin et al. \[[@B22]\] also found that *XRCC2*-deficient cancer cells were more sensitive to irradiation *in vitro* and speculated that the inhibition of *XRCC2* expression or activity represents a potential therapeutic strategy for improving preoperative radiotherapy responses in patients with locally advanced rectal cancer. These results strongly suggest that *XRCC2* plays an important role not only in the development of the cancer but also in radiotherapy outcomes.

*MSH2* is an important MMR gene and several studies have suggested that variations in *MSH2* are associated with sensitivity to radiotherapy and disease progression in rectal cancer patients \[[@B23], [@B24]\]. However, the present study found that there was no association between two SNPs in this gene (rs2303424 and rs2303425) and the efficacy of radiotherapy. Xie et al. \[[@B25]\] also found that there was no correlation between survival time and *MSH2* gene expression levels in patients with NSCLC who were treated with chemotherapy, which is consistent with our results. SNPs in the *XPD* gene have been widely studied and suggested to be genomic markers to predict the response to radiation dose and potentially guide personalized radiotherapy \[[@B18], [@B26]\]. This study also discovered that *XPD* rs13181 was associated with the progression and outcomes of patients with NSCLC after radiotherapy. Patients carrying the rs13181 GT genotype who were treated with radiotherapy had a high level of toxic reaction coupled with low efficacy.

Despite the positive findings, there are also some limitations in this study. First, we were unable to explain how the DNA repair gene variations influenced the outcomes of radiotherapy. Secondly, too few SNPs were genotyped. We selected the potentially functional SNPs based on three criteria so that the SNPs did not cover all SNPs in the entire gene. Thirdly, our sample size is still too small. In this study, we failed to replicate the association between *MSH2* and NSCLC patients. This could be due to the genetic heterogeneity in different population and a small number of samples included. Fourthly, gene--gene and gene--environment interactions were not analyzed. Additionally, some other important genes, such as *ATM* gene of DNA-damage sensing \[[@B27]\], *ATG16L2* gene related to autophagy \[[@B28]\], and *RUNX3* \[[@B29]\] gene in the methionine metabolic pathway that have been reported to be associated with the outcomes of NSCLS, were not included in this study.

In conclusion, we have identified patients with NSCLC carrying the rs25487 (*XRCC1*), rs3218556 (*XRCC2*), and rs13181 (*XPD*) SNPs, which appear to contribute to the efficacy and toxicity of radiotherapy. Our findings may be helpful in understanding the predictive value of examining DNA repair genes in the prognosis of patients with NSCLC after radiotherapy. Further investigation of more genes and samples should be carried out to confirm our findings. In addition, more studies should be implemented to explain the underlying molecular mechanisms to explain how these polymorphisms affect the response to radiotherapy and prospective clinical trials in patients with NSCLC.
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###### 

Supplementary Table 1: genomic function of the ten SNPs in XRCC1, XRCC2, MSH2, and XPD genes.

###### 

Click here for additional data file.

###### 

Clinical characteristics and demographics of the NSCLC patients.

  Characteristic                 NSCLC patients (*n* = 486)
  ------------------------------ ----------------------------
  Age (years)                    62 (33--84)
  Gender (%)                      
   Male                          328 (67.5%)
   Female                        158 (32.5%)
  Smoke history (%)               
   Smokers                       244 (50.2%)
   Never smokers                 242 (49.8%)
  Histology (%)                   
   Squamous cell carcinoma       307 (63.2%)
   Adenocarcinoma                179 (36.8%)
  Family history of cancer (%)    
   Yes                           76 (15.7%)
   No                            410 (84.3%)
  Chemotherapy (%)                
   Yes                           383 (78.8%)
   No                            103 (21.2%)
  Response (%)                    
   Response (CR + PR)            234 (48.1%)
   Nonresponse (SD + PD)         252 (51.9%)

###### 

Association between candidate SNPs and efficacy of radiotherapy.

  Gene        SNPs        Genotype   CR + PR                SD + PD     OR (95% CI)   *p*
  ----------- ----------- ---------- ---------------------- ----------- ------------- -----------
  *XRCC1*     rs25487     CC         130                    111         Reference     Reference
  CT          81          98         0.706 (0.479--1.041)   0.078                     
  TT          23          43         0.457 (0.259--0.804)   **0.006**                 
  CT + TT     104         141        0.630 (0.440--0.901)   **0.011**                 
  rs25489     CC          190        203                    Reference   Reference     
  CT          42          47         0.955 (0.602--1.514)   0.844                     
  TT          2           2          1.068 (0.149--7.661)   0.947                     
  CT + TT     44          49         0.959 (0.610--1.509)   0.858                     
  rs1799782   GG          128        121                    Reference   Reference     
  AG          84          97         0.819 (0.558--1.201)   0.306                     
  AA          22          34         0.612 (0.339--1.105)   0.101                     
  AG + AA     106         131        0.765 (0.535--1.093)   0.141                     
  rs3213245   AA          182        181                    Reference   Reference     
  AG          53          66         0.799 (0.527--1.211)   0.289                     
  GG          3           5          0.597 (0.141--2.534)   0.479                     
  AG + GG     56          71         0.784 (0.523--1.178)   0.241                     
  *XRCC2*     rs3218544   GG         82                     78          Reference     Reference
  AG          114         133        0.815 (0.547--1.214)   0.315                     
  AA          38          41         0.882 (0.514--1.512)   0.647                     
  AG + AA     152         174        0.831 (0.569--1.214)   0.338                     
  rs3218385   AA          172        172                    Reference   Reference     
  AC          53          73         0.726 (0.481--1.096)   0.127                     
  CC          9           7          1.286 (0.468--3.530)   0.625                     
  AC + CC     62          80         0.775 (0.523--1.148)   0.203                     
  rs3218556   GG          166        149                    Reference   Reference     
  AG          57          77         0.664 (0.442--0.999)   **0.049**                 
  AA          11          26         0.380 (0.181--0.795)   **0.008**                 
  AG + AA     68          103        0.593 (0.406--0.865)   **0.006**                 
  *MSH2*      rs2303424   GG         86                     102         Reference     Reference
  AG          117         129        1.076 (0.735--1.574)   0.707                     
  AA          31          20         1.599 (0.868--2.945)   0.131                     
  AG + AA     148         149        1.178 (0.817--1.699)   0.380                     
  rs2303425   TT          147        166                    Reference   Reference     
  CT          72          62         1.311 (0.874--1.968)   0.190                     
  CC          15          24         0.706 (0.357--1.396)   0.315                     
  CT + CC     87          86         1.142 (0.788--1.657)   0.483                     
  *XPD*       rs238419    CC         79                     95          Reference     Reference
  CT          101         110        1.104 (0.738--1.651)   0.629                     
  TT          54          47         1.382 (0.845--2.259)   0.197                     
  CT + TT     155         157        1.187 (0.818--1.722)   0.366                     
  rs13181     TT          176        209                    Reference   Reference     
  GT          56          40         1.663 (1.057--2.614)   **0.027**                 
  GG          2           3          0.792 (0.131--4.791)   0.799                     
  GT + GG     58          43         1.602 (1.029--2.493)   **0.036**                 

The *p* values in bold represent a statistically significant association. All data are adjusted for age, gender, smoking history, cancer histology, family history, and treatment with chemotherapy.

###### 

Association between candidate SNPs and radiation-induced toxic reactions.

  Gene        SNPs        Genotype   Low toxic reactions    High toxic reactions   OR (95% CI)   *p*
  ----------- ----------- ---------- ---------------------- ---------------------- ------------- -----------
  *XRCC1*     rs25487     CC         188                    74                     Reference     Reference
  CT          114         69         0.650 (0.435--0.972)   **0.035**                            
  TT          23          18         0.503 (0.257--0.986)   **0.043**                            
  CT + TT     137         87         0.620 (0.424--0.907)   **0.013**                            
  rs25489     CC          257        122                    Reference              Reference     
  CT          65          38         0.812 (0.515--1.279)   0.369                                
  TT          3           1          0.424 (0.147--13.83)   0.759                                
  CT + TT     68          39         0.828 (0.528--1.297)   0.409                                
  rs1799782   GG          175        91                     Reference              Reference     
  AG          117         58         1.049 (0.700--1.571)   0.817                                
  AA          33          12         1.430 (0.705--2.902)   0.320                                
  AG + AA     150         70         1.114 (0.762--1.630)   0.577                                
  rs3213245   AA          248        117                    Reference              Reference     
  AG          74          43         0.812 (0.525--1.255)   0.348                                
  GG          3           1          1.415 (0.146--13.75)   0.764                                
  AG + GG     77          44         0.826 (0.537--1.270)   0.383                                
  *XRCC2*     rs3218544   GG         117                    49                     Reference     Reference
  AG          162         83         0.817 (0.534--1.251)   0.353                                
  AA          46          28         0.688 (0.387--1.224)   0.202                                
  AG + AA     208         111        0.785 (0.523--1.177)   0.241                                
  rs3218385   AA          235        109                    Reference              Reference     
  AC          78          47         0.770 (0.502--1.180)   0.229                                
  CC          12          5          1.113 (0.383--3.238)   0.844                                
  AC + CC     90          52         0.803 (0.533--1.210)   0.293                                
  rs3218556   GG          238        96                     Reference              Reference     
  AG          78          52         0.605 (0.396--0.924)   **0.019**                            
  AA          9           13         0.279 (0.116--0.675)   **0.003**                            
  AG + AA     87          65         0.540 (0.362--0.805)   **0.002**                            
  *MSH2*      rs2303424   GG         123                    52                     Reference     Reference
  AG          156         82         0.804 (0.528--1.224)   0.309                                
  AA          46          27         0.720 (0.405--1.280)   0.263                                
  AG + AA     202         109        0.783 (0.526--1.168)   0.230                                
  rs2303425   TT          204        106                    Reference              Reference     
  CT          104         45         1.201 (0.788--1.830)   0.394                                
  CC          17          10         0.883 (0.391--1.997)   0.765                                
  CT + CC     121         55         1.143 (0.769--1.698)   0.508                                
  *XPD*       rs238419    CC         102                    43                     Reference     Reference
  CT          149         77         0.816 (0.520--1.280)   0.375                                
  TT          74          41         0.761 (0.451--1.283)   0.304                                
  CT + TT     223         118        0.797 (0.523--1.213)   0.289                                
  rs13181     TT          235        130                    Reference              Reference     
  GT          82          27         1.680 (1.035--2.728)   **0.035**                            
  GG          8           4          1.106 (0.327--3.745)   0.871                                
  GT + GG     90          31         1.624 (1.025--2.547)   **0.038**                            

The *p* values in bold indicate a statistically significant association. All data are adjusted for age, gender, smoking history, cancer histology, family history, and treatment with chemotherapy.
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